Trial Profile

A phase II study of PRAX-628 for treatment of focal epilepsy

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 17 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vormatrigine (Primary)
Indications Epilepsy; Partial epilepsies
Focus Adverse reactions
Sponsors Praxis Precision Medicines

Most Recent Events

13 May 2024 According to a Praxis Precision Medicines media release, top-line results expected in 2025.
26 Mar 2024 According to a Praxis Precision Medicines media release, company plans to initiate an efficacy study in focal onset epilepsy in the second half of 2024
07 Aug 2023 According to a Praxis Precision Medicines media release, this study is expected to initiate in the first half of 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com